CoChat
Sign Up
Cited by 837

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals

Homayun, Bahman, Lin, Xueting, Choi, Hyo-Jick·2019·Pharmaceutics
DOI 10.3390/pharmaceutics11030129PMC PMC6471246
Open this paper in CoChat — free account

Abstract

Routes of drug administration and the corresponding physicochemical characteristics of a given route play significant roles in therapeutic efficacy and short term/long term biological effects. Each delivery method has favorable aspects and limitations, each requiring a specific delivery vehicles design. Among various routes, oral delivery has been recognized as the most attractive method, mainly due to its potential for solid formulations with long shelf life, sustained delivery, ease of administration and intensified immune response. At the same time, a few challenges exist in oral delivery, which have been the main research focus in the field in the past few years. The present work concisely reviews different administration routes as well as the advantages and disadvantages of each method, highlighting why oral delivery is currently the most promising approach. Subsequently, the present work discusses the main obstacles for oral systems and explains the most recent solutions proposed to deal with each issue.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics11030129

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 3 references

Research works printed but not linked: 222

  1. Siafaka, 2015, Chitosan derivatives as effective nanocarriers for ocular release of timolol drug, Int. J. Pharm., 495, 249, 10.1016/j.ijpharm.2015.08.100 · DOI
  2. Borchard, R.T. (1992). Volume 1: Protein pharmacokinetics and metabolism. Pharmaeutical Biotechnology., Springer Science+Business Media, LLC.
  3. Kassies, 2016, Penetration and delivery characteristics of repetitive microjet injection into the skin, J. Control. Release, 234, 98, 10.1016/j.jconrel.2016.05.019 · DOI
  4. Rodger, 2000, Drawing up and administering intramuscular injections: A review of the literature, J. Adv. Nurs., 31, 574, 10.1046/j.1365-2648.2000.01312.x · DOI
  5. Mishra, 2010, Sciatic nerve injury from intramuscular injection: A persistent and global problem, Int. J. Clin. Pract., 64, 1573, 10.1111/j.1742-1241.2009.02177.x · DOI
  6. Nicoll, 2002, Intramuscular injection: An integration research review and guideline for evidence-based practice, Appl. Nurs. Res., 16, 149, 10.1053/apnr.2002.34142 · DOI
  7. Liang, 2016, Local innate immune responses in the vaccine adjuvant-injected muscle, Clin. Transl. Immunol., 5, 74, 10.1038/cti.2016.19 · DOI
  8. Herzog, 1997, Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus, Proc. Natl. Acad. Sci. USA, 94, 5804, 10.1073/pnas.94.11.5804 · DOI
  9. Nanaki, 2017, PLGA/SBA-15 mesoporous silica composite microparticles loaded with paclitaxel for local chemotherapy, Eur. J. Pharm. Sci., 99, 32, 10.1016/j.ejps.2016.12.010 · DOI
  10. Nanaki, 2017, Use of mesoporous cellular foam (MCF) in preparation of polymeric microspheres for long acting injectable release formulations of paliperidone antipsychotic drug, Eur. J. Pharm. Biopharm., 117, 77, 10.1016/j.ejpb.2017.03.016 · DOI
  11. Fletcher, 2018, Sustained delivery of anti-VEGF from injectable hydrogel systems provides a prolonged decrease of endothelial cell proliferation and angiogenesis in vitro, RSC Adv., 8, 8999, 10.1039/C7RA13014G · DOI
  12. Moeller, 2008, Alternative routes of administration for systemic delivery of protein pharmaceuticals, Drug Discov. Today Technol., 5, 89, 10.1016/j.ddtec.2008.11.005 · DOI
  13. Kale, 2014, Needle free injection technology—An overview, Inov. Pharm., 5, 1, 10.24926/iip.v5i1.330 · DOI
  14. Brown, 2006, Dermal and transdermal drug delivery systems: Current and future prospects, Drug Deliv., 13, 175, 10.1080/10717540500455975 · DOI
  15. Ranade, 1991, Drug delivery systems. 6. Transdermal drug delivery, J. Clin. Pharmacol., 31, 401, 10.1002/j.1552-4604.1991.tb01895.x · DOI
  16. Nerantzaki, 2018, Design of a multifunctional nanoengineered PLLA surface by maximizing the synergies between biochemical and surface design bactericidal effects, ACS Omega, 3, 1509, 10.1021/acsomega.7b01756 · DOI
  17. Kim, 2018, Nasal vaccine delivery (Chapter fifteen), Appl. Sci. Eng., 1, 1
  18. Lee, 1998, Photomechanical transcutaneous delivery of macromolecules, J. Invest. Dermatol., 111, 925, 10.1046/j.1523-1747.1998.00415.x · DOI
  19. Prausnitz, 2008, Transdermal drug delivery, Nat. Biotechnol., 26, 1261, 10.1038/nbt.1504 · DOI
  20. Chen, 2014, Novel chemical permeation enhancers for transdermal drug delivery, Asian J. Pharm. Sci., 9, 51, 10.1016/j.ajps.2014.01.001 · DOI
  21. Karande, 2006, Insights into synergistic interactions in binary mixtures of chemical permeation enhancers for transdermal drug delivery, J. Control. Release, 115, 85, 10.1016/j.jconrel.2006.07.001 · DOI
  22. Maxwell, 2006, Complications of blood transfusion, Contin. Educ. Anaesth. Crit. Care Pain, 6, 225, 10.1093/bjaceaccp/mkl053 · DOI
  23. Korttila, 1980, Venous complications after intravenous injection of diazepam, flunitrazepam, thiopentone and etomidate, Acta Anaesthesiol. Scand., 24, 227, 10.1111/j.1399-6576.1980.tb01540.x · DOI
  24. Awate, 2013, Mechanisms of action of adjuvants, Front. Immunol., 4, 1, 10.3389/fimmu.2013.00114 · DOI
  25. Harshad, 2010, Recent techniques in nasal drug delivery: A review, Int. J. Drug Dev. Res., 2, 565
  26. Nanaki, S., Tseklima, M., Christodoulou, E., Triantafyllidis, K., Kostoglou, M., and Bikiaris, D.N. (2017). Thiolated chitosan masked polymeric microspheres with incorporated mesocellular silica foam (MCF) for intranasal delivery of paliperidone. Polymers, 9. · DOI
  27. Buenestado, 2012, Intranasal drug delivery: An efficient and non-invasive route for systemic administration Focus on opioids, Pharmacol. Ther., 134, 366, 10.1016/j.pharmthera.2012.03.003 · DOI · Paper page
  28. Bhise, 2008, Bioavailability of intranasal drug delivery system, Asian J. Pharm., 2, 201, 10.4103/0973-8398.45032 · DOI
  29. Ramvikas, M., Arumugam, M., Chakrabarti, S.R., and Jaganathan, K.S. (2017). Nasal vaccine delivery (Chapter fifteen). Micro- and Nanotechnology in Vaccine Development, Elsevier Inc. · DOI
  30. Bakri, 2018, Overview of intranasally delivered peptides: Key considerations for pharmaceutical development, Expert Opin. Drug Deliv., 15, 991, 10.1080/17425247.2018.1517742 · DOI
  31. Choi, 2014, The osmotic stress response of split influenza vaccine particles in an acidic environment, Arch. Pahrmacal Res., 37, 1607, 10.1007/s12272-013-0257-5 · DOI
  32. Banerjee, 2016, Role of nanoparticle size, shape and surface chemistry in oral drug delivery, J. Control. Release, 238, 176, 10.1016/j.jconrel.2016.07.051 · DOI
  33. Pedro, 2017, Functionalized materials for multistage platforms in the oral delivery of biopharmaceuticals, Prog. Mater. Sceince, 89, 306, 10.1016/j.pmatsci.2017.05.001 · DOI
  34. Hu, 2018, Recent advances of polysaccharide-based nanoparticles for oral insulin delivery, Int. J. Biol. Macromol., 120, 775, 10.1016/j.ijbiomac.2018.08.152 · DOI
  35. Choi, 2013, A mechanistic study on the destabilization of whole inactivated influenza virus vaccine in gastric environment, PLoS ONE, 8, 1
  36. Schenk, 2008, The mucosal immune system at the gastrointestinal barrier, Best Pract. Res., 22, 391, 10.1016/j.bpg.2007.11.002 · DOI
  37. Ensign, 2012, Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers, Adv. Drug Deliv. Rev., 64, 557, 10.1016/j.addr.2011.12.009 · DOI
  38. Leal, 2017, Physicochemical properties of mucus and their impact on transmucosal drug delivery, Int. J. Pharm., 532, 555, 10.1016/j.ijpharm.2017.09.018 · DOI · Paper page
  39. Fievez, 2006, Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach, J. Control. Release, 116, 1, 10.1016/j.jconrel.2006.08.013 · DOI · Paper page
  40. Kwon, 2016, Oral delivery of protein drugs bioencapsulated in plant cells, Mol. Ther., 24, 1342, 10.1038/mt.2016.115 · DOI
  41. Ma, 2018, Oral recombinant Lactobacillus vaccine targeting the intestinal microfold cells and dendritic cells for delivering the core neutralizing epitope of porcine epidemic diarrhea virus, Microb. Cell Fact., 17, 1, 10.1186/s12934-018-0861-7 · DOI
  42. Maharjan, 2016, Systemic administration of RANKL overcomes the bottleneck of oral vaccine delivery through microfold cells in ileum, Biomaterials, 84, 286, 10.1016/j.biomaterials.2016.01.043 · DOI
  43. Varum, 2008, Mucoadhesion and the gastrointestinal tract, Crit. Rev. Ther. Drug Carrier Syst., 25, 207, 10.1615/CritRevTherDrugCarrierSyst.v25.i3.10 · DOI
  44. Dawson, 2004, Transport of polymeric nanoparticle gene carriers in gastric mucus, Biotechnol. Prog., 20, 851, 10.1021/bp0342553 · DOI
  45. Hounnou, 2002, Anatomical study of the length of the human intestine, Surg. Radiol. Anat., 24, 290, 10.1007/s00276-002-0057-y · DOI
  46. Helander, 2014, Surface area of the digestive tract – revisited, Scand. J. Gastroenterol., 49, 681, 10.3109/00365521.2014.898326 · DOI · Paper page
  47. Mudie, 2010, Physiological parameters for oral delivery and in vitro testing, Mol. Pharm., 7, 1388, 10.1021/mp100149j · DOI
  48. Vllasaliu, 2018, Recent advances in oral delivery of biologics: Nanomedicine and physical modes of delivery, Expert Opin. Drug Deliv., 15, 759, 10.1080/17425247.2018.1504017 · DOI
  49. Tao, 2005, Micromachined devices: The impact of controlled geometry from cell-targeting to bioavailability, J. Control. Release, 109, 127, 10.1016/j.jconrel.2005.09.019 · DOI
  50. Rzhevskiy, 2018, Microneedles as the technique of drug delivery enhancement in diverse organs and tissues, J. Control. Release, 270, 184, 10.1016/j.jconrel.2017.11.048 · DOI
  51. Dimmitt, R.A., Sellers, Z.M., and Sibley, E. (2012). XIV-Gastrointestinal system-70 Gastrointestinal tract development. Avery’s Diseases of the Newborn, Elsevier Inc.
  52. Treuting, P.M., Dintzis, S.M., and Montine, K. (2018). Upper gastrointestinal tract. Comparative Anatomy and Histology (Second Edition), A Mouse, Rat, and Human Atlas, Academic Press, Elsevier. · DOI
  53. Cheng, 1974, Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine, Am. J. Anat., 141, 481, 10.1002/aja.1001410404 · DOI
  54. Lennernas, 1998, Human intestinal permeability, Int. J. Pharm. Sci., 87, 403
  55. Podolsky, D.K., Camilleri, M., Shanahan, F., Fitz, J.G., Wang, T.C., and Kalloo, A.N. (2016). Anatomy and development-small intestine: Anatomy and structural anomalies. Yamada’s Atlas of Gastroenterology, Wiley Blackwell. · DOI
  56. Dressman, 1990, Upper gastrointestinal (GI) pH in young, healthy men and women, Pharm. Res., 7, 756, 10.1023/A:1015827908309 · DOI
  57. Rouge, 1996, Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery, Int. J. Pharm., 136, 117, 10.1016/0378-5173(96)85200-8 · DOI
  58. Moroz, 2016, Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts, Adv. Drug Deliv. Rev., 101, 108, 10.1016/j.addr.2016.01.010 · DOI
  59. Assaraf, 2016, β-casein nanovehicles for oral delivery of chemotherapeutic drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells, Oncotarget, 7, 23322, 10.18632/oncotarget.8019 · DOI
  60. Huang, 2015, Layer-by-layer assembled milk protein coated magnetic nanoparticle enabled oral drug delivery with high stability in stomach and enzyme-responsive release in small intestine, Biomaterials, 39, 105, 10.1016/j.biomaterials.2014.10.059 · DOI
  61. Ruiz, 2016, Denaturation and in vitro gastric digestion of heat-treated quinoa protein isolates obtained at various extraction pH, Food Biophys., 11, 184, 10.1007/s11483-016-9429-4 · DOI
  62. Yamagata, 2006, Characterization of insulin protection properties of complexation hydrogels in gastric and intestinal enzyme fluids, J. Control. Release, 112, 343, 10.1016/j.jconrel.2006.03.005 · DOI
  63. Cerchiara, 2016, Microparticles based on chitosan/carboxymethylcellulose polyelectrolyte complexes for colon delivery of vancomycin, Carbohydr. Polym., 143, 124, 10.1016/j.carbpol.2016.02.020 · DOI
  64. Bourre, 2011, Intestinal delivery of non-viral gene therapeutics: Physiological barriers and preclinical models, Drug Discov. Today, 16, 203, 10.1016/j.drudis.2011.01.003 · DOI
  65. Rawlings, 1994, Families of serine peptidases, Methods in Enzymology, Volume 244, 19, 10.1016/0076-6879(94)44004-2 · DOI · Paper page
  66. Davies, 2017, Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes a randomized clinical trial, J. Am. Med. Assoc., 318, 1460, 10.1001/jama.2017.14752 · DOI · Paper page
  67. Layer, 1986, Fate of pancreatic enzymes aboral transit in humans during small intestinal aboral transit in humans, Am. J. Physiol., 251, 475
  68. Fallingborg, 1989, pH-profile and regional transit fimes of the normal gut measured by a radiotelemetry device, Aliment. Pharmacol. Ther., 3, 605, 10.1111/j.1365-2036.1989.tb00254.x · DOI
  69. Bermejo, 2018, PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen, Eur. J. Pharm. Sci., 115, 119, 10.1016/j.ejps.2017.12.009 · DOI
  70. Valon, 2019, Dying under pressure: Cellular characterisation and in vivo functions of cell death induced by compaction, Biol. Cell, 111, 1, 10.1111/boc.201800075 · DOI
  71. Chan, 2016, Enhanced mechanical properties in cellulose nanocrystal−poly(oligoethylene glycol methacrylate) injectable nanocomposite hydrogels through control of physical and chemical cross-linking, Biomacromolecules, 17, 649, 10.1021/acs.biomac.5b01598 · DOI
  72. Yang, 2013, Revealing strong nanocomposite hydrogels reinforced by cellulose nanocrystals: Insight into morphologies and interactions, Appl. Mater. Interfaces, 5, 12960, 10.1021/am403669n · DOI
  73. Mert, 2012, A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles, J. Control. Release, 157, 455, 10.1016/j.jconrel.2011.08.032 · DOI
  74. Liu, 2018, Mucus adhesion- and penetration-enhanced liposomes for paclitaxel oral delivery, Int. J. Pharm., 537, 245, 10.1016/j.ijpharm.2017.12.044 · DOI
  75. Shan, 2015, Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin, ACS Nano, 9, 2345, 10.1021/acsnano.5b00028 · DOI
  76. Liu, 2016, Efficient mucus permeation and tight junction opening by dissociable “mucus-inert” agent coated trimethyl chitosan nanoparticles for oral insulin delivery, J. Control. Release, 222, 67, 10.1016/j.jconrel.2015.12.008 · DOI
  77. Leal, 2018, Mucus-penetrating phage-displayed peptides for improved transport across a mucus-like model, Int. J. Pharm., 553, 57, 10.1016/j.ijpharm.2018.09.055 · DOI
  78. Zhang, 2018, Design and intestinal mucus penetration mechanism of core-shell nanocomplex, J. Control. Release, 272, 29, 10.1016/j.jconrel.2017.12.034 · DOI
  79. Navarro, 2018, Advances in mucin mimic synthesis and applications in surface science, Curr. Opin. Colloid Interface Sci., 38, 122, 10.1016/j.cocis.2018.09.004 · DOI
  80. Kufe, 2009, Mucins in cancer: Function, prognosis and therapy Donald, Nat. Rev. Cancer, 9, 874, 10.1038/nrc2761 · DOI
  81. Atuma, 2001, The adherent gastrointestinal mucus gel layer: Thickness and physical state in vivo, Am. J. Physiol. Liver Physiol., 280, 922
  82. Chassaing, 2019, Identification of inner mucus-associated bacteria by laser capture microdissection, Cell. Mol. Gastroenterol. Hepatol., 7, 157, 10.1016/j.jcmgh.2018.09.009 · DOI
  83. Bansil, 2018, The biology of mucus: Composition, synthesis and organization, Adv. Drug Deliv. Rev., 124, 3, 10.1016/j.addr.2017.09.023 · DOI
  84. Boegh, 2015, Steric and interactive barrier properties of intestinal mucus elucidated by particle diffusion and peptide permeation, Eur. J. Pharm. Biopharm., 95, 136, 10.1016/j.ejpb.2015.01.014 · DOI
  85. Hansson, 2010, V The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria, Gut Microbes, 1, 51, 10.4161/gmic.1.1.10470 · DOI
  86. Johansson, 2011, The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host–microbial interactions, PNAS, 108, 4659, 10.1073/pnas.1006451107 · DOI
  87. Bajka, 2015, The influence of small intestinal mucus structure on particle transport ex vivo, Colloids Surf. B Biointerfaces, 135, 73, 10.1016/j.colsurfb.2015.07.038 · DOI
  88. Li, 2011, Novel mucus-penetrating liposomes as a potential oral drug delivery system: Preparation, in vitro characterization, and enhanced cellular uptake, Int. J. Nanomed., 6, 3151
  89. Cu, 2009, Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus, Mol. Pharm., 6, 173, 10.1021/mp8001254 · DOI
  90. Muller, 2013, Preparation and characterization of mucus-penetrating papain/poly(acrylic acid) nanoparticles for oral drug delivery applications, J. Nanopart. Res., 15, 1353, 10.1007/s11051-012-1353-z · DOI
  91. DeSousa, 2015, Nanoparticles decorated with proteolytic enzymes, a promising strategy to overcome the mucus barrier, Eur. J. Pharm. Biopharm., 97, 257, 10.1016/j.ejpb.2015.01.008 · DOI
  92. Moreno, 2018, Development of electrosprayed mucoadhesive chitosan microparticles, Carbohydr. Polym., 190, 240, 10.1016/j.carbpol.2018.02.062 · DOI
  93. Park, 2017, Nanostructured mucoadhesive microparticles to enhance oral drug bioavailability, J. Ind. Eng. Chem., 54, 262, 10.1016/j.jiec.2017.06.001 · DOI
  94. Krauland, 2006, Thiolated chitosan microparticles: A vehicle for nasal peptide drug delivery, Int. J. Pharm., 307, 270, 10.1016/j.ijpharm.2005.10.016 · DOI
  95. Romero, 2016, Development of cationic nanocrystals for ocular delivery, Eur. J. Pharm. Biopharm., 107, 215, 10.1016/j.ejpb.2016.07.005 · DOI
  96. Paines, 2017, Novel Pemulen/Pullulan blended hydrogel containing clotrimazole-loaded cationic nanocapsules: Evaluation of mucoadhesion and vaginal permeation, Mater. Sci. Eng. C, 79, 886, 10.1016/j.msec.2017.05.030 · DOI
  97. Kim, 2015, Chitosan-catechol: A polymer with long-lasting mucoadhesive properties, Biomaterials, 52, 161, 10.1016/j.biomaterials.2015.02.010 · DOI
  98. Ertl, 2000, Lectin-mediated bioadhesion: Preparation, stability and Caco-2 binding of wheat germ agglutinin-functionalized poly(D,L-lactic-co-glycolic acid)-microspheres, J. Drug Target., 8, 173, 10.3109/10611860008996863 · DOI
  99. Anirudhan, 2018, Novel thiolated chitosan-polyethyleneglycol blend/Montmorillonite composite formulations for the oral delivery of insulin, Bioact. Carbohydr. Diet. Fibre, 16, 22, 10.1016/j.bcdf.2018.02.003 · DOI
  100. Hornof, 2004, Thiolated chitosans, Eur. J. Pharm. Biopharm., 57, 9, 10.1016/S0939-6411(03)00147-4 · DOI
  101. Deutel, 2016, In vitro characterization of insulin containing thiomeric microparticles as nasal drug delivery system, Eur. J. Pharm. Sci., 81, 157, 10.1016/j.ejps.2015.10.022 · DOI
  102. Sajeesh, 2010, Thiol functionalized polymethacrylic acid-based hydrogel microparticles for oral insulin delivery, Acta Biomater., 6, 3072, 10.1016/j.actbio.2010.02.007 · DOI
  103. Farris, 2018, Oral non-viral gene delivery for applications in DNA vaccination and gene therapy, Curr. Opin. Biomed. Eng., 7, 51, 10.1016/j.cobme.2018.09.003 · DOI
  104. Batista, 2018, Recent insights in the use of nanocarriers for the oral delivery of bioactive proteins and peptides, Peptides, 101, 112, 10.1016/j.peptides.2018.01.002 · DOI
  105. Zhang, 2012, Thiolated Eudragit nanoparticles for oral insulin delivery: Preparation, characterization and in vivo evaluation, Int. J. Pharm., 436, 341, 10.1016/j.ijpharm.2012.06.054 · DOI
  106. Cone, 2009, Barrier properties of mucus, Adv. Drug Deliv. Rev., 61, 75, 10.1016/j.addr.2008.09.008 · DOI
  107. Huckaby, 2018, PEGylation for enhancing nanoparticle diffusion in mucus, Adv. Drug Deliv. Rev., 124, 125, 10.1016/j.addr.2017.08.010 · DOI
  108. Jung, 2000, Biodegradable nanoparticles for oral delivery of peptides: Is there a role for polymers to affect mucosal uptake?, Eur. J. Pharm. Biopharm., 50, 147, 10.1016/S0939-6411(00)00084-9 · DOI
  109. Lai, 2009, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv. Drug Deliv. Rev., 61, 158, 10.1016/j.addr.2008.11.002 · DOI
  110. Zhaeentana, 2018, The effects of hydrocortisone on tight junction genes in an in vitro model of the human fallopian epithelial cells, Eur. J. Obstet. Gynecol. Reprod. Biol., 229, 127, 10.1016/j.ejogrb.2018.05.034 · DOI
  111. Bein, 2018, Intestinal tight junctions are severely altered in NEC preterm neonates, Pediatr. Neonatol., 59, 464, 10.1016/j.pedneo.2017.11.018 · DOI
  112. Gamboa, 2013, In vitro and in vivo models for the study of oral delivery of nanoparticles, Adv. Drug Deliv. Rev., 65, 800, 10.1016/j.addr.2013.01.003 · DOI
  113. Linnankoski, 2010, Paracellular porosity and pore size of the human intestinal epithelium in tissue and cell culture models, J. Pharm. Sci., 99, 2166, 10.1002/jps.21961 · DOI
  114. Salama, 2006, Tight junction modulation and its relationship to drug delivery, Adv. Drug Deliv. Rev., 58, 15, 10.1016/j.addr.2006.01.003 · DOI · Paper page
  115. Kim, 2014, Emulsion-based colloidal nanosystems for oral delivery of doxorubicin: Improved intestinal paracellular absorption and alleviated cardiotoxicity, Int. J. Pharm., 464, 117, 10.1016/j.ijpharm.2014.01.016 · DOI
  116. Taverner, 2015, Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation, J. Control. Release, 210, 189, 10.1016/j.jconrel.2015.05.270 · DOI
  117. Almansour, 2018, Mechanistic studies of a cell-permeant peptide designed to enhance myosin light chain phosphorylation in polarized intestinal epithelia, J. Control. Release, 279, 208, 10.1016/j.jconrel.2018.03.033 · DOI
  118. Banerjee, 2017, Intestinal patch systems for oral drug delivery, Curr. Opin. Pharmacol., 36, 58, 10.1016/j.coph.2017.08.005 · DOI
  119. Banerjee, 2016, Intestinal mucoadhesive devices for oral delivery of insulin, Bioeng. Transl. Med., 1, 338, 10.1002/btm2.10015 · DOI
  120. Shen, 2002, Intestinal patches for oral drug delivery, Pharm. Res., 19, 391, 10.1023/A:1015118923204 · DOI
  121. Toorisaka, 2005, An enteric-coated dry emulsion formulation for oral insulin delivery, J. Control. Release, 107, 91, 10.1016/j.jconrel.2005.05.022 · DOI
  122. Toorisaka, 2012, Intestinal patches with an immobilized solid-in-oil formulation for oral protein delivery, Acta Biomater., 8, 653, 10.1016/j.actbio.2011.09.023 · DOI
  123. Lee, 2018, Drug delivery using microneedle patches: Not just for skin, Expert Opin. Drug Deliv., 15, 541, 10.1080/17425247.2018.1471059 · DOI
  124. Ma, 2014, Vaccine delivery to the oral cavity using coated microneedles induces systemic and mucosal immunity, Pharm. Res., 31, 2393, 10.1007/s11095-014-1335-1 · DOI
  125. Traverso, 2015, Microneedles for Drug Delivery via the Gastrointestinal Tract, J. Pharm. Sci., 104, 362, 10.1002/jps.24182 · DOI
  126. Dabholkar, 2006, Polyethylene glycol–phosphatidylethanolamine conjugate (PEG–PE)-based mixed micelles: Some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux, Int. J. Pharm., 315, 148, 10.1016/j.ijpharm.2006.02.018 · DOI
  127. Yu, 2015, pH- and NIR light-responsive micelles with hyperthermia-triggered tumor penetration and cytoplasm drug release to reverse doxorubicin resistance in breast cancer, Adv. Funct. Mater., 25, 2489, 10.1002/adfm.201404484 · DOI
  128. Suzuki, 2016, Evaluation of drug penetration with cationic micelles and their penetration mechanism using an in vitro tumor model, Biomaterials, 98, 120, 10.1016/j.biomaterials.2016.04.037 · DOI
  129. Sosnik, 2015, Polymeric micelles in mucosal drug delivery: Challenges towards clinical translation, Biotechnol. Adv., 33, 1380, 10.1016/j.biotechadv.2015.01.003 · DOI · Paper page
  130. Torchilin, 2005, Fluorescence microscopy to follow the targeting of liposomes and micelles to cells and their intracellular fate, Adv. Drug Deliv. Rev., 57, 95, 10.1016/j.addr.2004.06.002 · DOI
  131. Byrne, 2002, Use of commercial porous ceramic particles for sustained drug delivery, Int. J. Pharm., 246, 61, 10.1016/S0378-5173(02)00357-5 · DOI
  132. Hoffman, 2012, Hydrogels for biomedical applications, Adv. Drug Deliv. Rev., 64, 18, 10.1016/j.addr.2012.09.010 · DOI · Paper page
  133. Li, 2016, Designing hydrogels for controlled drug delivery, Nat. Rev. Mater., 1, 1, 10.1038/natrevmats.2016.71 · DOI
  134. Chai, Q., Jiao, Y., and Yu, X. (2017). Hydrogels for biomedical applications: Their characteristics and the mechanisms behind them. Gels, 3. · DOI
  135. Khutoryanskiy, 2015, Biomedical applications of hydrogels: A review of patents and commercial products, Eur. Polym. J., 65, 252, 10.1016/j.eurpolymj.2014.11.024 · DOI · Paper page
  136. Klouda, 2015, Thermoresponsive hydrogels in biomedical applications A seven-year update, Eur. J. Pharm. Biopharm., 97, 338, 10.1016/j.ejpb.2015.05.017 · DOI
  137. Peppas, 1999, Molecular design and in vitro studies of novel pH-sensitive hydrogels for the oral delivery of calcitonin, Macromolecules, 32, 6646, 10.1021/ma990541c · DOI
  138. Simpson, 2018, Narrowly dispersed, degradable, and scalable poly(oligoethylene glycol methacrylate)-based nanogels via thermal self-assembly, Ind. Eng. Chem. Res., 57, 7495, 10.1021/acs.iecr.8b00793 · DOI
  139. Choi, 2017, Telodendrimers for physical encapsulation and covalent linking of individual or combined therapeutics, Mol. Pharm., 14, 2607, 10.1021/acs.molpharmaceut.7b00019 · DOI
  140. DeFrance, 2018, Structured macroporous hydrogels: Progress, challenges, and opportunities, Adv. Healthc. Mater., 7, 1
  141. Annabi, 2010, Controlling the porosity and microarchitecture of hydrogels for tissue engineering, Tissue Eng. Part B, 16, 371, 10.1089/ten.teb.2009.0639 · DOI
  142. Kim, 2004, Structure and properties of silk hydrogels, Biomacromolecules, 5, 786, 10.1021/bm0345460 · DOI
  143. Yokoyama, 1986, Morphology and structure of highly elastic poly(vinyl alcohol) hydrogel prepared by repeated freezing-and-melting, Colloid Polym. Sci., 601, 595, 10.1007/BF01412597 · DOI
  144. Hermansson, 1981, Characterization of protein gels by scanning and transmission electron microscopy, J. Colloid Interface Sci., 81, 510, 10.1016/0021-9797(81)90433-1 · DOI
  145. Jeong, 2005, Polymer hollow particles with controllable holes in their surfaces, Nat. Mater., 4, 671, 10.1038/nmat1448 · DOI
  146. Staruch, 2017, Injectable pore-forming hydrogel scaffolds for complex wound tissue engineering: Designing and controlling their porosity and mechanical properties, Tissue Eng. Part B, 23, 183, 10.1089/ten.teb.2016.0305 · DOI
  147. Loh, 2013, Three-dimensional scaffolds for tissue engineering applications: Role of porosity and pore size, Tissue Eng. Part B, 19, 485, 10.1089/ten.teb.2012.0437 · DOI · Paper page
  148. Li, 2014, Engineering cell alignment in vitro, Biotechnol. Adv., 32, 347, 10.1016/j.biotechadv.2013.11.007 · DOI
  149. Vlierberghe, 2007, Porous gelatin hydrogels: 1. Cryogenic formation and structure analysis, Biomacromolecules, 8, 331, 10.1021/bm060684o · DOI
  150. Lai, 2010, Functional assessment of cross-linked porous gelatin hydrogels for bioengineered cell sheet carriers, Biomacromolecules, 11, 1387, 10.1021/bm100213f · DOI
  151. Lewus, 2001, Protein transport in constrained anionic hydrogels: Diffusion and boundary-layer mass transfer, Ind. Eng. Chem. Res., 40, 1548, 10.1021/ie0006054 · DOI
  152. Pundir, 2013, Sustained release matrix technology and recent advance in matrix drug delivery system: A review, Int. J. Drug Res. Technol., 3, 12
  153. Thedrattanawong, 2018, Controlling the burst release of doxorubicin from polymeric depots via adjusting hydrophobic/hydrophilic properties, J. Drug Deliv. Sci. Technol., 46, 446, 10.1016/j.jddst.2018.06.001 · DOI
  154. Li, 2017, Liposomes coated with thiolated chitosan as drug carriers of curcumin, Mater. Sci. Eng. C, 80, 156, 10.1016/j.msec.2017.05.136 · DOI
  155. Martins, 2017, Mucoadhesive properties of thiolated pectin-based pellets prepared by extrusion-spheronization technique, J. Pharm. Sci., 106, 1363, 10.1016/j.xphs.2017.01.028 · DOI
  156. Lichtenberger, 1995, The hydrophobic barrier properties of gastrointestinal mucus, Annu. Rev. Physiol., 57, 565, 10.1146/annurev.ph.57.030195.003025 · DOI
  157. Traverso, 2015, Special delivery for the gut, Nature, 519, S19, 10.1038/519S19a · DOI
  158. Lam, 2014, Advanced progress of microencapsulation technologies: In vivo and in vitro models for studying oral and transdermal drug deliveries, J. Control. Release, 178, 25, 10.1016/j.jconrel.2013.12.028 · DOI
  159. Salessiotis, 1972, Measurement of the diameter of the Pylorus in man: Part I. Experimental project for clinical application, Am. J. Surg., 124, 331, 10.1016/0002-9610(72)90036-0 · DOI
  160. Sultan, 1969, Esophageal diameter and the treatment of achalasia, Am. J. Dig. Dis., 14, 611, 10.1007/BF02239272 · DOI
  161. Zhang, 2015, A pH-responsive supramolecular polymer gel as an enteric elastomer for use in gastric devices, Nat. Mater., 14, 1065, 10.1038/nmat4355 · DOI
  162. Naraykin, 2018, Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles, Eur. J. Pharm. Biopharm., 133, 214, 10.1016/j.ejpb.2018.10.013 · DOI
  163. Pena, 2017, Alginate microparticles as oral colon drug delivery device: A review, Carbohydr. Polym., 168, 32, 10.1016/j.carbpol.2017.03.033 · DOI
  164. Chen, 2018, Facile fabrication of bowl-shaped microparticles for oral curcumin delivery to ulcerative colitis tissue, Colloids Surf. B Biointerfaces, 169, 92, 10.1016/j.colsurfb.2018.05.012 · DOI
  165. Nadal, 2016, Spray-dried Eudragit® L100 microparticles containing ferulic acid: Formulation, in vitro cytoprotection and in vivo anti-platelet effect, Mater. Sci. Eng. C, 64, 318, 10.1016/j.msec.2016.03.086 · DOI
  166. Ratzinger, 2010, Surface modification of PLGA nanospheres with Gd-DTPA and Gd-DOTA for high-relaxivity MRI contrast agents, Biomaterials, 31, 8716, 10.1016/j.biomaterials.2010.07.095 · DOI
  167. Koch, B., Rubino, I., Quan, F.-S., Yoo, B., and Choi, H.-J. (2016). Microfabrication for drug delivery. Materials, 9. · DOI
  168. Noguchi, 2001, Fusion pathways of vesicles: A Brownian dynamics simulation, J. Chem. Phys., 115, 9547, 10.1063/1.1414314 · DOI
  169. Pekarek, 1994, Double-walled polymer microspheres for controlled drug release, Nature, 367, 258, 10.1038/367258a0 · DOI
  170. Wong, 2002, Assembly of nanoparticles into hollow spheres using block copolypeptides, Nano Lett., 2, 583, 10.1021/nl020244c · DOI
  171. Du, 2009, Advances and challenges in smart and functional polymer vesicles, Soft Matter, 5, 3544, 10.1039/b905635a · DOI
  172. Yokoyama, 1989, Molecular design for missile drug: Synthesis of adriamycin conjugated with immunoglobulin G using poly(ethylene glycol)-block-poly(aspartic acid) as intermediate carrier, Die Makromol. Chemie, 190, 2041, 10.1002/macp.1989.021900904 · DOI
  173. Batycky, 1997, A theoretical model of erosion and macromolecular drug release from biodegrading microspheres, J. Pharm. Sci., 86, 1464, 10.1021/js9604117 · DOI · Paper page
  174. Steijn, 2013, Block-and-break generation of microdroplets with fixed volume, Biomicrofluidics, 7, 24108, 10.1063/1.4801637 · DOI
  175. Abbaspourrad, 2013, Polymer microcapsules with programmable active release, J. Am. Chem. Soc., 135, 7744, 10.1021/ja401960f · DOI
  176. Ostafe, 2014, A high-throughput cellulase screening system based on droplet microfluidics, Biomicrofluidics, 8, 041102, 10.1063/1.4886771 · DOI
  177. Bitar, C., Markwick, K.E., and Hoesli, C.A. (2017, January 3–6). Encapsulation of Pancreatic Islet Cells for Type 1 Diabetes Treatment. Proceedings of the XXV International Conference on Bioencapsulation, Nantes, France. Available online: http://bioencapsulation.net/221_newsletters/Bioencap_innov_2017_11/Bioencap_innov_2017_11.pdf.
  178. Deng, 2014, Reply to the ‘Comment on “Wetting-induced formation of controllable monodisperse multiple emulsions in microfluidics”’ by J. Guzowski and P.; Garstecki, Lab Chip, 2014, 14, DOI:10.1039/ C3LC51229K, Lab Chip, 14, 1479, 10.1039/C4LC00028E · DOI
  179. Massenburg, 2016, Clogging in parallelized tapered microfluidic channels, Microfluid. Nanofluidics, 20, 1, 10.1007/s10404-016-1758-6 · DOI
  180. Wyss, 2006, Mechanism for clogging of microchannels, Phys. Rev. E, 74, 1, 10.1103/PhysRevE.74.061402 · DOI
  181. Kumar, 2017, Smart microparticles with a pH-responsive macropore for targeted oral drug delivery, Sci. Rep., 7, 061402
  182. Caruso, 2001, Nanoengineering of particle surfaces, Adv. Mater., 13, 11, 10.1002/1521-4095(200101)13:1<11::AID-ADMA11>3.0.CO;2-N · DOI
  183. Cai, 2013, Porous microsphere and its applications, Int. J. Nanomed., 8, 1111
  184. Ferrari, M., Lee, A., and Lee, J. (2006). Volume I: Biological and biomedical nanotechnology-Microspheres for drug delivery. BioMEMS and Biomedical Nanotechnology, Springer. · DOI
  185. Homayun, 2018, Facile fabrication of microparticles with pH-responsive macropores for small intestine targeted drug formulation, Eur. J. Pharm. Biopharm., 128, 316, 10.1016/j.ejpb.2018.05.014 · DOI
  186. Homayun, 2018, Macropored microparticles with a core–shell architecture for oral delivery of biopharmaceuticals, Arch. Pharm. Res., 41, 848, 10.1007/s12272-018-1062-y · DOI
  187. Chen, 2009, Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells, Small, 5, 2673, 10.1002/smll.200900621 · DOI
  188. Wang, 2015, Mesoporous silica nanoparticles in drug delivery and biomedical applications, Nanomed. Nanotechnol. Biol. Med., 11, 313, 10.1016/j.nano.2014.09.014 · DOI · Paper page
  189. Lai, 2003, A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules, J. Am. Chem. Soc., 125, 4451, 10.1021/ja028650l · DOI
  190. Chen, 2011, Double mesoporous silica shelled spherical/ellipsoidal nanostructures: Synthesis and hydrophilic/hydrophobic anticancer drug delivery, J. Mater. Chem., 21, 5290, 10.1039/c0jm04024j · DOI
  191. Zhao, 2009, Mesoporous silica nanoparticle-based double drug delivery system for glucose responsive controlled release of insulin and cyclic AMP, J. Am. Chem. Soc., 131, 8398, 10.1021/ja901831u · DOI
  192. Teo, 2016, Co-delivery of drugs and plasmid DNA for cancer therapy, Adv. Drug Deliv. Rev., 98, 41, 10.1016/j.addr.2015.10.014 · DOI
  193. Kang, 2011, Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy, Pharm. Res., 28, 3069, 10.1007/s11095-011-0569-4 · DOI
  194. Cao, 2013, Enhanced antitumor response mediated by the codelivery of paclitaxel and adenoviral vector expressing IL-12, Mol. Pharm., 10, 1804, 10.1021/mp300602j · DOI
  195. Mamaeva, 2013, Mesoporous silica nanoparticles in medicine-Recent advances, Adv. Drug Deliv. Rev., 65, 689, 10.1016/j.addr.2012.07.018 · DOI
  196. Santos, 2018, Halloysite clay nanotubes for life sciences applications: From drug encapsulation to bioscaffold, Adv. Colloid Interface Sci., 257, 58, 10.1016/j.cis.2018.05.007 · DOI
  197. Slowing, 2008, Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers, Adv. Drug Deliv. Rev., 60, 1278, 10.1016/j.addr.2008.03.012 · DOI
  198. Kresge, 1992, Ordered mesoporous molecular sieves synthesized by a liquid crystal template mechanism, Nature, 359, 710, 10.1038/359710a0 · DOI
  199. Inagaki, 1993, Synthesis of highly ordered mesoporous materials from a layered polysilicate, J. Chem. Soc. Chem. Commun., 8, 680, 10.1039/c39930000680 · DOI
  200. Gaaz, 2015, Properties and applications of polyvinyl alcohol, halloysite nanotubes and their nanocomposites, Molecules, 20, 22833, 10.3390/molecules201219884 · DOI

200 of 222 shown

Cited by

Sorted by citations

See all 837

Metadata

Authors
Homayun, B., Lin, X., & Choi, H.-J.
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2019-03-19
Volume
11
Issue
3
Pages
129
ISSN
1999-4923
DOI
10.3390/pharmaceutics11030129
PMC
PMC6471246
Cited by
837
References
3
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
Alberta Innovates - Technology Futures (AIF200900279)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review